# Phase 2 Carcinoma, Hepatocellular trials: 195 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 195 trials in phase 2 for Carcinoma, Hepatocellular that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Carcinoma, Hepatocellular trials: 195 rows for $9.75, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 195
- Recruiting or not yet: 195
- Read on: November 19, 2026

## Trials

The 25 newest of 195, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940478 | A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for... | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Hepatecellular Carcinoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940478) |
| November 12, 2026 | NCT07933016 | QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933016) |
| November 5, 2026 | NCT07919717 | NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919717) |
| November 4, 2026 | NCT07917481 | A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917481) |
| November 3, 2026 | NCT07911683 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 2 | Not yet recruiting | Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911683) |
| October 21, 2026 | NCT07884877 | PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer | Samsung Medical Center | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884877) |
| October 20, 2026 | NCT07882056 | SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882056) |
| September 23, 2026 | NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced... | University of Southern California | Phase 2 | Not yet recruiting | Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836712) |
| September 21, 2026 | NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832006) |
| September 21, 2026 | NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829926) |
| September 18, 2026 | NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC | Chang Gung Memorial Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827807) |
| September 3, 2026 | NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | HCC - Hepatocellular Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801287) |
| August 28, 2026 | NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma | Anhui Provincial Hospital | Phase 2 | Recruiting | Hepatocellular Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793695) |
| August 20, 2026 | NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | HCC - Hepatocellular Carcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776080) |
| August 19, 2026 | NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma | CHA University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774247) |
| August 6, 2026 | NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Advanced Unresectable Hepatocellular Carcinoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749859) |
| July 27, 2026 | NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | Sun Yat-sen University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729592) |
| July 9, 2026 | NCT07691645 | Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691645) |
| July 8, 2026 | NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689175) |
| July 7, 2026 | NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687914) |
| July 2, 2026 | NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | University of California, San Francisco | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Liver Cancer, Adult | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682454) |
| June 23, 2026 | NCT07663487 | A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to... | Sirtex Medical | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663487) |
| June 18, 2026 | NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657273) |
| June 12, 2026 | NCT07644208 | PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07644208) |
| June 10, 2026 | NCT07639138 | Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | Sponsor not shown (see the record) | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639138) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Tianjin Medical University Cancer Institute and Hospital | 11 |
| Second Affiliated Hospital of Guangzhou Medical University | 10 |
| Sun Yat-sen University | 9 |
| Tongji Hospital | 5 |
| Chang Gung Memorial Hospital | 5 |
| Fudan University | 4 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 4 |
| University of Texas Southwestern Medical Center | 4 |
| Peking Union Medical College Hospital | 4 |
| Asan Medical Center | 3 |
| Northern Jiangsu People's Hospital | 3 |
| Seoul National University Hospital | 3 |
| Shanghai Zhongshan Hospital | 3 |
| Anhui Provincial Hospital | 3 |
| Fujian Cancer Hospital | 3 |
| First Affiliated Hospital of Wenzhou Medical University | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 2 |
| CHA University | 2 |
| Northwestern University | 2 |
| Mayo Clinic | 2 |
| National Taiwan University Hospital | 2 |
| Nanfang Hospital, Southern Medical University | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |

## By country

| Country | Trials |
| --- | --- |
| China | 94 |
| United States | 37 |
| South Korea | 13 |
| Taiwan | 11 |
| France | 6 |
| Germany | 4 |
| Canada | 4 |
| United Kingdom | 3 |
| Singapore | 3 |
| Italy | 3 |
| Spain | 3 |
| Netherlands | 3 |
| Australia | 2 |
| Hong Kong | 1 |
| Norway | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Rubber and plastics manufacturers in the United States](https://specstream.ai/data/businesses/rubber-and-plastics-manufacturers/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Glass companies in the United States](https://specstream.ai/data/businesses/glass-companies/united-states)
- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Australian restaurants in the United States](https://specstream.ai/data/businesses/australian-restaurants/united-states)
